Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic

RA Kessler, MA Mealy, M Levy - Current treatment options in neurology, 2016 - Springer
Opinion statement Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune
disease of the central nervous system that primarily attacks the optic nerves and spinal cord …

[HTML][HTML] Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology

ML Fichtner, R Jiang, A Bourke, RJ Nowak… - Frontiers in …, 2020 - frontiersin.org
Myasthenia gravis (MG) is a prototypical autoantibody mediated disease. The
autoantibodies in MG target structures within the neuromuscular junction (NMJ), thus …

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 …

MA Agius, G Klodowska-Duda… - Multiple Sclerosis …, 2019 - journals.sagepub.com
Background: B cells may be involved in the pathophysiology of multiple sclerosis (MS).
Inebilizumab (formerly MEDI-551) binds to and depletes CD19+ B cells. Objectives: To …

B cell checkpoints in autoimmune rheumatic diseases

SJS Rubin, MS Bloom, WH Robinson - Nature Reviews Rheumatology, 2019 - nature.com
B cells have important functions in the pathogenesis of autoimmune diseases, including
autoimmune rheumatic diseases. In addition to producing autoantibodies, B cells contribute …

B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets

TG Forsthuber, DM Cimbora… - Therapeutic …, 2018 - journals.sagepub.com
Increasing recognition of the role of B cells in the adaptive immune response makes B cells
an important therapeutic target in autoimmunity. Numerous current and developmental …

Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production

E Cotzomi, P Stathopoulos, CS Lee, AM Ritchie… - Brain, 2019 - academic.oup.com
Neuromyelitis optica spectrum disorders (NMOSD) constitute rare autoimmune disorders of
the CNS that are primarily characterized by severe inflammation of the spinal cord and optic …

[HTML][HTML] Inebilizumab, a B cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies

D Chen, S Gallagher, NL Monson, R Herbst… - Journal of clinical …, 2016 - mdpi.com
Exaggerated or inappropriate responses by B cells are an important feature in many types of
autoimmune neurological diseases. The recent success of B-cell depletion in the treatment …

[HTML][HTML] Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy

ML Fichtner, KB Hoehn, EE Ford… - Acta neuropathologica …, 2022 - Springer
Myasthenia gravis (MG) is an autoantibody-mediated autoimmune disorder of the
neuromuscular junction. A small subset of patients (< 10%) with MG, have autoantibodies …

Influence of the gut microbiome on autoimmunity in the central nervous system

SL Colpitts, LH Kasper - The Journal of Immunology, 2017 - journals.aai.org
Autoimmune disorders of the CNS have complex pathogeneses that are not well
understood. In multiple sclerosis and neuromyelitis optica spectrum disorders, T cells …

B cells in multiple sclerosis therapy—A comprehensive review

R Rahmanzadeh, MS Weber, W Brück… - Acta Neurologica …, 2018 - Wiley Online Library
For decades, B cells were ignored in multiple sclerosis (MS) pathogenesis, and the disease
was always regarded as a T cell‐mediated disorder. Recent evidence shows that there is an …